Get the Stockscreener App
0.591
4.68%
-0.029
Lyell Immunopharma Inc Stock (LYEL) Latest News
Take off with Lyell Immunopharma Inc (LYEL): Get ready for trading - SETE News
LYEL underperforms with a -0.98 decrease in share price - US Post News
Market Momentum Report: Lyell Immunopharma Inc (LYEL)’s Negative Close at 0.58 - The Dwinnex
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake - Yahoo Finance
Lyell Immunopharma Faces Nasdaq delisting over share price - MSN
Lyell Immunopharma Faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Barclays PLC Has $332,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma price target lowered to 60c from $1 at BofA - MSN
Lyell Immunopharma stock hits 52-week low at $0.58 - Investing.com India
Lyell to Highlight Vision for its Next-Generation CAR - GlobeNewswire
Lyell's IMPT-314 Cancer Therapy Shows 94% Response Rate, Plans Pivotal Trials for Lymphoma - StockTitan
Jane Street Group LLC Buys 111,917 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Barclays PLC Has $332,000 Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
State Street Corp Has $5.37 Million Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell' - GuruFocus.com
Charles Schwab Investment Management Inc. Trims Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Fmr LLC - Defense World
Fmr LLC Has $1.41 Million Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - MarketBeat
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround - Yahoo Finance
Lyell Immunopharma stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Lyell Immunopharma stock hits 52-week low at $0.85 - Investing.com India
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial - StockTitan
Lyell Presents Positive Initial Clinical Data from the - GlobeNewswire
Form 424B5 Lyell Immunopharma, Inc. - StreetInsider.com
Intech Investment Management LLC Acquires New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
SEC Form S-3 filed by Lyell Immunopharma Inc. - Quantisnow
Lyell Immunopharma Reports Resignation of Board Member - Defense World
Lyell Immunopharma Director Hans bishop resigns - Investing.com
Lyell Immunopharma Director Hans bishop resigns By Investing.com - Investing.com Australia
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga
Lyell Immunopharma: Q3 Earnings Snapshot - AOL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - The Manila Times
Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks
Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):